10.07.10
Laureate Pharma, Inc. has secured $20 million to finance five investment initiatives over the course of three years. "This marks a significant milestone in our efforts to relaunch Laureate Pharma," said Michael A. Griffith, chief executive officer. "Our strategically planned improvements coupled with our solid financial footing will position us for exceptional growth. As we transform Laureate, care will be taken to maintain continuity of client services. Quality Assurance will oversee investment activities to ensure our offerings comply with the strict demands of global regulatory agencies."
The company’s investments include: upgrading aseptic fill capabilities (planned for early 2012) with a new segregated fill suite with a fully-automated fill line incorporating vial washing, depyrogenation, filling, and capping, upgrading protein production services to increase bioreactor (2000L) and purification (10L chromatography skid) capacity, launching a contract analytical testing business offering a full range of testing required to characterize protein products, expanding mammalian cell line creation services, as well as adding cGMP cell banking services, and adopting new quality systems technologies to better manage inventory, deviations, and calibration and validation. The company also plans to expand its regulatory affairs unit to assist clients in the preparation of data summaries, batch reports and regulatory submissions.
Laureate has recently added 10 new jobs and plans to fill 50 more positions when working at capacity.
Click here to learn more about Laureate
The company’s investments include: upgrading aseptic fill capabilities (planned for early 2012) with a new segregated fill suite with a fully-automated fill line incorporating vial washing, depyrogenation, filling, and capping, upgrading protein production services to increase bioreactor (2000L) and purification (10L chromatography skid) capacity, launching a contract analytical testing business offering a full range of testing required to characterize protein products, expanding mammalian cell line creation services, as well as adding cGMP cell banking services, and adopting new quality systems technologies to better manage inventory, deviations, and calibration and validation. The company also plans to expand its regulatory affairs unit to assist clients in the preparation of data summaries, batch reports and regulatory submissions.
Laureate has recently added 10 new jobs and plans to fill 50 more positions when working at capacity.
Click here to learn more about Laureate